The idea of identifying Alzheimer’s disease through a blood draw once sounded distant. It is now part of clinical practice, but the headline needs an important second sentence: a blood test does not, by itself, tell the whole story of a person’s memory. In May 2025, the U.S. Food and Drug Administration cleared the first blood test intended to aid in diagnosing Alzheimer’s disease. The Lumipulse G pTau217/β-amyloid 1-42 Plasma Ratio measures two blood markers whose relationsh

When a headline says someone can control a computer with their mind, it can sound like science fiction. The real science is narrower and, in some ways, more moving: researchers are trying to restore everyday choices to people who have lost the ability to speak or move. A brain–computer interface, or BCI, records patterns of brain activity and uses software to translate them into an action, such as moving a cursor or forming words on a screen. Neuralink is one company studying

Last year, Neuro-Reach wrote about why Texas Proposition 14 mattered before voters went to the polls. Now the question has changed. Texans approved the measure in November 2025, authorizing a $3 billion Dementia Prevention and Research Fund and the Dementia Prevention and Research Institute of Texas (DPRIT). What should families expect from that decision? The law gives DPRIT a broad mission. Its research scope includes dementia, Alzheimer’s disease, Parkinson’s disease, and r

On January 18, 2025, Neuro-Reach brought a brain-health education seminar to the West University Place Community Building and Senior Center. The event combined three practical opportunities: a conversation about memory and aging, voluntary cognitive screenings, and individual help using phones and tablets to find information. Each part addressed a question people may face after noticing a change in themselves or someone they love: What should I pay attention to? What can a br

Last weekend, Neuro-Reach hosted an Alzheimer’s and cognitive screening workshop at the Leonel Castillo Community Center , bringing together student volunteers, healthcare professionals, and local residents for a day focused on brain health awareness and early detection . Our team of student volunteers screened more than 50 seniors using a simplified version of the Montreal Cognitive Assessment (MoCA) , a brief and research-based tool used to identify early signs of Alzhei

This November, Texans have an opportunity to take a historic step toward improving public health and advancing scientific discovery by voting Yes on Proposition 14. This constitutional amendment would allocate $3 billion over the next decade to establish the Dementia Prevention and Research Institute of Texas (DPRIT), a groundbreaking initiative designed to fund research, prevention, and care efforts for Alzheimer’s and related neurological diseases. If approved, Proposition

Researchers have completed the most comprehensive circuit diagram of a mammalian brain fragment ever created. A U.S. team successfully mapped a tiny slice of a mouse's visual cortex, uncovering: 84,000 neurons 500 million synapses 5.4 kilometers of intricate neural wiring This effort represents a monumental leap forward in our ability to understand brain organization — not just in mice, but eventually in humans as well. By comparing healthy vs. diseased neural wiring at such

In a place like Houston, where cutting-edge medicine thrives just a short drive away in the Texas Medical Center, it's easy to assume...

On Sunday, November 10th 2024; Neuro-Reach joined members of Clear Lake First Baptist Church in Houston for a community workshop focused on memory, aging, and the value of recognizing cognitive changes early. The gathering brought brain-health education into a familiar setting where neighbors could ask questions without first having to navigate a specialty clinic. Our student volunteers welcomed participants, helped them check in, and shared printed information on common sign

In July 2024, the U.S. Food and Drug Administration approved donanemab, sold as Kisunla, for people with early symptomatic Alzheimer’s disease. The treatment targets amyloid, a protein that builds up in the brains of many people with Alzheimer’s. In a clinical trial, the group receiving donanemab had slower clinical decline over 76 weeks than the placebo group. That is meaningful progress. It is also different from a cure. The distinction matters to families deciding what to